<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="test groups - those who test positive for active SARS-CoV-2" exact="infection" post="(using molecular methods) and those who test negative for"/>
 <result pre="(using molecular methods) and those who test negative for current" exact="infection" post="but also test positive for past infection (using serologic"/>
 <result pre="negative for current infection but also test positive for past" exact="infection" post="(using serologic antibody tests). Patients from each of these"/>
 <result pre="having potential prophylactic, therapeutic, or contraindicated effects with respect to" exact="disease" post="progression. These drugs could then be selected as candidates"/>
 <result pre="to extensive. The archetype example is the historic 1854 London" exact="cholera" post="outbreak, where Dr. John Snow was able to identify"/>
 <result pre="usage rate for each test group is significantly higher or" exact="lower" post="than the usage rates for the other groups. Usage"/>
 <result pre="and perhaps others that have adverse effects. To explain the" exact="lower" post="incidence of serious Covid-19 outcomes compared with favorable outcomes,"/>
 <result pre="the short-term therapy might overlap with different intervals of the" exact="disease" post="progression would make interpretation of collected data much more"/>
 <result pre="upon whether they tested positive or negative for active SARS-CoV-2" exact="infection" post="or tested positive for past SARS-CoV-2 infection (see Table"/>
 <result pre="for active SARS-CoV-2 infection or tested positive for past SARS-CoV-2" exact="infection" post="(see Table 1 ). Patients would provide a list"/>
 <result pre="as vaccines. Table 1 Few combinations of tests are of" exact="primary" post="use in mining drug usage data for NERD. Table"/>
 <result pre="data for NERD. Table 1 Option Positive test for ACTIVE" exact="infection" post="(RT-PCR) Negative test for ACTIVE infection (RT- PCR) Positive"/>
 <result pre="Positive test for ACTIVE infection (RT-PCR) Negative test for ACTIVE" exact="infection" post="(RT- PCR) Positive test for PAST infection (antibody) Negative"/>
 <result pre="test for ACTIVE infection (RT- PCR) Positive test for PAST" exact="infection" post="(antibody) Negative test for PAST infection (antibody) Morbidities #1"/>
 <result pre="Positive test for PAST infection (antibody) Negative test for PAST" exact="infection" post="(antibody) Morbidities #1 â€&quot; not applicable asymptomatic to mild"/>
 <result pre="these might have a greater chance for adversely affecting the" exact="pulmonary" post="system. It might seem that drugs of obvious interest"/>
 <result pre="guided by known or postulated pathways of exposure, infection, or" exact="disease" post="progression, as NERD would essentially test all drugs for"/>
 <result pre="evolving knowledge of SARS-CoV-2 infection, where a major route of" exact="infection" post="is believed to be pulmonary (via angiotensin converting enzyme"/>
 <result pre="where a major route of infection is believed to be" exact="pulmonary" post="(via angiotensin converting enzyme 2 - ACE2 - receptors),"/>
 <result pre="converting enzyme 2 - ACE2 - receptors), leading to severe" exact="respiratory" post="inflammation. But ACE2 receptors not only populate alveolar epithelial"/>
 <result pre="severe respiratory inflammation. But ACE2 receptors not only populate alveolar" exact="epithelial" post="cells, but also endothelial cells, which means that various"/>
 <result pre="but also endothelial cells, which means that various organs and" exact="blood vessels" post="are vulnerable to inflammatory damage and clotting [21]. The"/>
 <result pre="potential for increasing the risk for developing overt signs of" exact="infection" post="or exacerbating clinical outcomes. The database would have to"/>
 <result pre="general categories of tests for Covid-19: tests that indicate active" exact="infection" post="and tests that primarily indicate past infection that has"/>
 <result pre="that indicate active infection and tests that primarily indicate past" exact="infection" post="that has resolved. The former currently relies on RT-PCR"/>
 <result pre="SARS-CoV-2; conceivable future tests would be those predicting vulnerability to" exact="disease" post="progression. These two groups provide complementary information for clinical,"/>
 <result pre="with a higher probability of success in repurposing. A very" exact="limited" post="number of possible combinations exist for how case groups"/>
 <result pre="negative for active infection, (2) positive or negative for past" exact="infection" post="(i.e., past infections that resolved via immune response with"/>
 <result pre="infection, (2) positive or negative for past infection (i.e., past" exact="infections" post="that resolved via immune response with display of little"/>
 <result pre="is the current gold standard for revealing whether an active" exact="infection" post="is underway, as it reveals viable, replicating virus; less"/>
 <result pre="higher throughput are emerging [1,28]. Antigen tests (e.g., based on" exact="viral" post="proteins released from the envelope or capsid) can also"/>
 <result pre="can indicate a graduated spectrum of possibilities, including whether an" exact="infection" post="had been cleared sometime in the past or that"/>
 <result pre="been cleared sometime in the past or that an active" exact="infection" post="is currently being resolved (assuming that more serious morbidities"/>
 <result pre="the US, where validation for specificity and sensitivity are critical." exact="Antibody" post="testing would also have to assume that pre-immunity was"/>
 <result pre="testing would yield a relatively definitive indication for an active" exact="infection" post="(especially with the presence of key signs or symptoms)."/>
 <result pre="signs or symptoms). In contrast, a negative test for active" exact="disease" post="(without any other complementary test) would not be useful"/>
 <result pre="for NERD. This is because negative-test cases would aggregate two" exact="primary" post="subgroups: (i) those who have never been exposed to"/>
 <result pre="and (ii) those who were infected but who resolved the" exact="infection" post="via a successful immune response (being asymptomatic or experiencing"/>
 <result pre="antibody testing (option #1 or #3); the course of the" exact="disease" post="can transition from infection-positive to infection-negative after testing immune-positive."/>
 <result pre="positive serum antibody test) that would be useful to NERD." exact="Antibody" post="tests provide additional opportunity for interpretation in NERD, as"/>
 <result pre="it were used in concert with a test of active" exact="infection" post="(option #2), would not provide any useful information for"/>
 <result pre="positive with subsequent testing), and (iv) those with an active" exact="infection" post="but the test yielded a false negative (because of"/>
 <result pre="(ii) potential for increasing the risk of developing more serious" exact="infection" post="or exacerbating clinical outcomes, and (iii) drugs that might"/>
 <result pre="might also make exposed individuals more susceptible to developing serious" exact="disease" post="(thereby allowing for more vigilance in avoiding exposure). A"/>
 <result pre="steroids; see: [13]). Conversely, also for the positive-test group, a" exact="lower" post="DxUR for a particular drug among severe and critical"/>
 <result pre="a function of the magnitude of the delivered dose of" exact="viral" post="particles. This exposure â€œintensityâ€� likely results in a continuum"/>
 <result pre="results in a continuum of severity of symptoms, rate of" exact="disease" post="progression, and modulation of disease outcomes. But this important"/>
 <result pre="severity of symptoms, rate of disease progression, and modulation of" exact="disease" post="outcomes. But this important aspect of Covid-19 is ignored"/>
 <result pre="indication that a drug might correlate with positive or negative" exact="disease" post="outcomes might instead simply be a confounding reflection of"/>
 <result pre="NERD include â€¢ Any knowledge of the pathogen itself or" exact="disease" post="progression would not be needed because NERD would rely"/>
 <result pre="symptoms. Very valuable data are therefore lost simply because of" exact="incomplete" post="medical records and lack of widespread testing [16]. Many"/>
 <result pre="they are advised to avoid testing because testing is in" exact="short" post="supply. â€¢ In the absence of widespread randomized testing"/>
 <result pre="testing because testing is in short supply. â€¢ In the" exact="absence of" post="widespread randomized testing of the asymptomatic population, drug usage"/>
 <result pre="NERD as presented here makes a liberal assumption that the" exact="total" post="population has full access to Rx and OTC drugs."/>
 <result pre="of administration. Examples for Covid-19 are drugs used for reducing" exact="lung inflammation" post="and damage, such as those required to fight cytokine"/>
 <result pre="a key parameter in inter-individual transmission. â€¢ Because the more" exact="limited" post="classes of drugs used in pediatric populations, it would"/>
 <result pre="NERD conclusions regarding drug usage rates. â€¢ Among the active" exact="infection" post="test group, a very small portion of the negative-test"/>
 <result pre="group may actually comprise newly infected cases (covert virus) whose" exact="viral" post="titers are insufficient to meet the minimum sensitivity for"/>
 <result pre="exposures to known environmental hazards (e.g., volatile algal toxins and" exact="pulmonary" post="toxicants such as atmospheric particulate matter and synthetic chemicals,"/>
 <result pre="might be especially germane to explaining cases of serious Covid-19" exact="disease" post="among healthy younger adults and reported gender and racial"/>
 <result pre="that are collectively consumed across entire communities. One of the" exact="primary" post="applications of WBE has been the monitoring of sewage"/>
 <result pre="sewage for drugs (or their metabolites) and back-calculating per capita" exact="consumption" post="[26]. WBE has also been used for monitoring the"/>
 <result pre="health [2,4] or for gauging community-wide status and trends of" exact="infection" post="[5]. WBE could therefore possibly be used to complement"/>
 <result pre="targeted for WBE monitoring in communities suspected as having low" exact="infection" post="rates; note that the overall rates of community infection"/>
 <result pre="low infection rates; note that the overall rates of community" exact="infection" post="could also be gauged by WBE (e.g., see: [18,32])."/>
 <result pre="targeted for WBE monitoring in communities suspected as having high" exact="infection" post="rates. Likewise, WBE could be used to quickly assess"/>
 <result pre="be used to quickly assess which communities may have high" exact="infection" post="rates, and then target these communities for testing of"/>
 <result pre="critical tools for timely detection, control, and mitigation of any" exact="disease" post="epidemic. Testing during epidemics provides rare opportunities to capitalize"/>
 <result pre="natural experiments for expanding what is known about exposure, transmission," exact="disease" post="progression, and therapeutic treatment. Presented here is a concept"/>
 <result pre="have higher probabilities of success in their re-purposing (re-positioning) for" exact="disease" post="prevention or clinical therapy - or conversely those drugs"/>
 <result pre="4DaughtonC.G.Monitoring wastewater for assessing community health: sewage chemical-information mining (SCIM)Sci." exact="Total" post="Environ.619â€&quot;620201874876410.1016/j.scitotenv.2017.11.102 5DaughtonC.The international imperative to rapidly and inexpensively monitor"/>
 <result pre="international imperative to rapidly and inexpensively monitor community- wide Covid-19" exact="infection" post="status and trendsSci. Total Environ.138149202010.1016/j.scitotenv.2020.138149 6BakerN.C.EkinsS.WilliamsA.J.TropshaA.A bibliometric review of"/>
 <result pre="and inexpensively monitor community- wide Covid-19 infection status and trendsSci." exact="Total" post="Environ.138149202010.1016/j.scitotenv.2020.138149 6BakerN.C.EkinsS.WilliamsA.J.TropshaA.A bibliometric review of drug repurposingDrug Discov. Today23201866167210.1016/j.drudis.2018.01.01829330123"/>
 <result pre="Switzerland 2020https://www.finddx.org/covid-19/ 9GeraciJ.HawillB.Candidate Drug, Dupilumab, To Mitigate COVID-19 Patients With" exact="Severe" post="Acute Respiratory Syndrome By Mitigating Cytokine Storm. OSF Preprints202010.31219/osf.io/hk7ep(19"/>
 <result pre="2020https://www.finddx.org/covid-19/ 9GeraciJ.HawillB.Candidate Drug, Dupilumab, To Mitigate COVID-19 Patients With Severe" exact="Acute" post="Respiratory Syndrome By Mitigating Cytokine Storm. OSF Preprints202010.31219/osf.io/hk7ep(19 March)"/>
 <result pre="9GeraciJ.HawillB.Candidate Drug, Dupilumab, To Mitigate COVID-19 Patients With Severe Acute" exact="Respiratory" post="Syndrome By Mitigating Cytokine Storm. OSF Preprints202010.31219/osf.io/hk7ep(19 March) 10GronvallG.Developing"/>
 <result pre="Drug, Dupilumab, To Mitigate COVID-19 Patients With Severe Acute Respiratory" exact="Syndrome" post="By Mitigating Cytokine Storm. OSF Preprints202010.31219/osf.io/hk7ep(19 March) 10GronvallG.Developing a"/>
 <result pre="understate the U.S. Coronavirus Death TollNew York Times2020(5 April)https://www.nytimes.com/2020/04/05/us/coronavirus-deaths-undercount.html 17LippiG.Sanchis-GomarF.HenryB.M.Coronavirus" exact="disease" post="2019 (COVID-19): the portrait of a perfect stormAnn. Transl."/>
 <result pre="Pandemic2020National Academies PressWashington DC10.17226/257758 April 20NASRapid Expert Consultation on SARS-CoV-2" exact="Viral" post="Shedding and Antibody Response for the COVID-19 Pandemic2020National Academies"/>
 <result pre="DC10.17226/257758 April 20NASRapid Expert Consultation on SARS-CoV-2 Viral Shedding and" exact="Antibody" post="Response for the COVID-19 Pandemic2020National Academies PressWashington DC10.17226/257748 April"/>
 <result pre="Today2020(24 March)https://www.medpagetoday.com/infectiousdisease/covid19/85577 22PizzornoA.PadeyB.TerrierO.Rosa-CalatravaM.Drug repurposing approaches for the treatment of influenza" exact="viral" post="infection: reviving old drugs to fight against a long-lived"/>
 <result pre="Safety Network, Rockville, MDhttps://psnet.ahrq.gov/primer/medication-reconciliationSeptember 2019 24ShameerK.GlicksbergB.S.HodosR.JohnsonK.W.BadgeleyM.A.ReadheadB.Systematic analyses of drugs and" exact="disease" post="indications in Repurpose DB reveal pharmacological, biological and epidemiological"/>
 <result pre="pandemicNat. Biotechnol.23 March 202010.1038/d41587-020-00010-2 26SimsN.Kasprzyk-HordernB.Future perspectives of wastewater-based epidemiology: monitoring" exact="infectious disease" post="spread and resistance to the community levelEnviron. Int.105689202010.1016/j.envint.2020.105689 27SmithM.D.SmithJ.C.Repurposing"/>
 <result pre="Biotechnol.23 March 202010.1038/d41587-020-00010-2 26SimsN.Kasprzyk-HordernB.Future perspectives of wastewater-based epidemiology: monitoring infectious" exact="disease" post="spread and resistance to the community levelEnviron. Int.105689202010.1016/j.envint.2020.105689 27SmithM.D.SmithJ.C.Repurposing"/>
 <result pre="Int.105689202010.1016/j.envint.2020.105689 27SmithM.D.SmithJ.C.Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2" exact="Viral" post="Spike Protein and Viral Spike Protein-Human ACE2 Interface202010.26434/chemrxiv.11871402.v3https://chemrxiv.org/articles/Repurposing_Therapeutics_for_the_Wuhan_Coronavirus_nCov-20 19_Supercomputer-Based_Docking_to_the_Viral_S_Protein_and_Human_ACE2_Interface/118"/>
 <result pre="Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike" exact="Protein" post="and Viral Spike Protein-Human ACE2 Interface202010.26434/chemrxiv.11871402.v3https://chemrxiv.org/articles/Repurposing_Therapeutics_for_the_Wuhan_Coronavirus_nCov-20 19_Supercomputer-Based_Docking_to_the_Viral_S_Protein_and_Human_ACE2_Interface/118 71402 28SuoT.LiuX.GuoM.FengJ.HuW.YangY.ddPCR:"/>
 <result pre="COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and" exact="Viral" post="Spike Protein-Human ACE2 Interface202010.26434/chemrxiv.11871402.v3https://chemrxiv.org/articles/Repurposing_Therapeutics_for_the_Wuhan_Coronavirus_nCov-20 19_Supercomputer-Based_Docking_to_the_Viral_S_Protein_and_Human_ACE2_Interface/118 71402 28SuoT.LiuX.GuoM.FengJ.HuW.YangY.ddPCR: a more"/>
 <result pre="more sensitive and accurate tool for SARS-CoV-2 detection in low" exact="viral" post="load specimensmedRxiv202010.1101/2020.02.29.20029439 29US FDACoronavirus (COVID-19) Update: FDA Continues to"/>
</results>
